{"product_id":"auroramj-pestle-analysis","title":"Aurora PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, economic trends, and emerging technologies are reshaping Aurora’s prospects in our concise PESTLE snapshot—perfect for investors and strategists seeking a quick edge. Purchase the full PESTLE analysis to unlock detailed risk assessments, regulatory impacts, and actionable recommendations you can use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS Federal Rescheduling Progress\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe potential US rescheduling of cannabis to Schedule III would materially cut tax drag from Section 280E; estimates suggest US cannabis companies face effective tax rates 20–40 percentage points higher, implying significant margin improvement for Aurora on US operations or exports.\u003c\/p\u003e\n\u003cp\u003eRescheduling would lower legal barriers to cross-border clinical trials and investment; FDA-authorized studies rose 15% in 2024, improving opportunities for Aurora’s R\u0026amp;D partnerships and licensing deals.\u003c\/p\u003e\n\u003cp\u003eAurora’s medical unit—20+ approved product lines and CAD 120m R\u0026amp;D runway as of FY2025—positions the company to capture expanded US therapeutic markets should federal policy liberalize.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGerman Medical Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Cannabis Act removed cannabis from Germany’s narcotics list in 2024, simplifying prescriptions and expanding patient access in Europe’s largest market of 83 million people; medical cannabis prescriptions rose about 40% in 2024 vs 2023. \u003c\/p\u003e\n\u003cp\u003eAurora, with GMP-certified supply and €45m FY2024 EU sales, leverages its German footprint while navigating EU trade and GMP export rules to sustain market leadership. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCanadian Excise Tax Reform Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical pressure is mounting on the federal government to reform the excise tax that now charges licensed producers by weight, costing Aurora and peers an estimated CAD 120–150 million in 2024 alone; industry lobbying seeks a shift to an ad valorem model tied to retail price. Aurora projects that successful reform could boost domestic gross margins by 6–10 percentage points and improve FY2025 EBITDA by CAD 40–70 million. Lobbying momentum includes cross-party support and stakeholder submissions submitted in 2024, increasing odds of change before end-2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade Liberalization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe emergence of medical cannabis frameworks in Australia (legalized federally in 2021 with a market projected to reach US$3.4bn by 2028) and Poland (expanded patient access in 2023) improves export prospects for Aurora, supporting revenue diversification beyond Canada where FY2024 international sales were ~10% of total.\u003c\/p\u003e\n\u003cp\u003eGrowing inclusion of cannabinoid medicines in trade agreements and bilateral health treaties reduces tariff and regulatory barriers, but Aurora must sustain diplomatic and regulatory ties to protect supply chains against geopolitical risks and trade disruptions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAustralia market: projected US$3.4bn by 2028\u003c\/li\u003e\n\u003cli\u003ePoland: patient access expanded 2023\u003c\/li\u003e\n\u003cli\u003eAurora FY2024 international sales ≈10% of revenue\u003c\/li\u003e\n\u003cli\u003ePriority: maintain regulatory\/diplomatic relationships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Research and Biotech Grants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic sector support for cannabinoid research creates a political tailwind for Aurora’s biotech and plant-science divisions, with Canada awarding over CAD 200m in health and cannabis research grants since 2018 and EU Horizon programs funding related projects at EUR 50–70m annually (2024–25).\u003c\/p\u003e\n\u003cp\u003eAccessing government grants for clinical cannabis efficacy—targeting chronic pain, MS, and epilepsy—lets Aurora secure non-dilutive R\u0026amp;D funding while positioning to influence evolving healthcare policies and reimbursement frameworks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCAD 200m+ Canadian grants since 2018\u003c\/li\u003e\n\u003cli\u003eEUR 50–70m EU funding\/year (2024–25)\u003c\/li\u003e\n\u003cli\u003eFocus: chronic pain, MS, epilepsy clinical trials\u003c\/li\u003e\n\u003cli\u003eNon-dilutive funding + policy influence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy shifts could slash barriers, boost Aurora’s margins and export growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical shifts—US rescheduling talks, German de-listing, and rising EU\/Australia medical frameworks—could cut tax and market barriers, boosting Aurora’s margins and export reach; FY2024 international sales ≈10%, CAD120–150m excise drag (2024), CAD200m+ Canadian research grants since 2018, EUR50–70m EU funding\/year (2024–25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl sales FY2024\u003c\/td\u003e\n\u003ctd\u003e≈10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExcise tax drag 2024\u003c\/td\u003e\n\u003ctd\u003eCAD120–150m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCanadian grants since 2018\u003c\/td\u003e\n\u003ctd\u003eCAD200m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU funding\/year 2024–25\u003c\/td\u003e\n\u003ctd\u003eEUR50–70m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental forces—Political, Economic, Social, Technological, Environmental, and Legal—specifically impact Aurora’s industry and region, with data-backed trends, actionable risks and opportunities, and forward-looking insights to inform strategy, funding and scenario planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary tailored for Aurora that can be dropped into presentations or shared across teams to quickly align on external risks and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePath to Positive Free Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora targets sustainable positive free cash flow by end-2025 after restructuring that cut cash burn from about US$250m in 2023 to an estimated US$40–60m run-rate in 2025, driven by divestitures of non-core assets and closure of inefficient facilities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Inflationary Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent global inflation lifted input costs for large-scale cannabis growers; Aurora reported COGS per gram rising ~8% YoY in FY2024 as energy and labor pressures pushed operating expenses higher. Management aims to avoid passing full increases to price-sensitive adult-use consumers—Canadian recreational average price fell ~2% in 2024—by accelerating automation and supply-chain consolidation, targeting a 10-15% reduction in manufacturing overhead by 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora, as a global exporter, is exposed to EUR\/CAD and USD\/CAD swings that in 2024 saw average daily volatility of ~0.8% and 0.9% respectively, affecting reported international medical revenue—FX translation reduced FY2024 revenue by an estimated CAD 18–25m—and raised 2024 foreign debt servicing costs by roughly CAD 6–9m; the company deploys hedging (forwards\/options covering ~60–75% of exposure) but macro instability remains a planning risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSector Consolidation and M\u0026amp;A Activity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe cannabis sector has seen rapid consolidation as smaller operators face liquidity strain; global M\u0026amp;A deal value in 2024 reached roughly $2.1bn, reflecting increased buyer activity.\u003c\/p\u003e\n\u003cp\u003eAurora acquired Bevo Farms to expand into horticulture and propagation, adding low-margin stable revenue; Aurora reported C$48m in non-cannabis segment revenue in FY2024, helping offset cannabis price compression.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 M\u0026amp;A ~US$2.1bn\u003c\/li\u003e\n\u003cli\u003eAurora FY2024 non-cannabis revenue C$48m\u003c\/li\u003e\n\u003cli\u003eDiversification reduces exposure to cannabis cyclical pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe prevailing high-interest-rate environment—US Fed funds around 5.25–5.50% in 2024—raises Aurora’s cost of capital, complicating refinancing of its roughly CAD 1.2 billion debt and slowing new infrastructure spending.\u003c\/p\u003e\n\u003cp\u003eHigher borrowing costs force conservative capex, prioritizing cash flow and deleveraging to protect margins as investors track a debt-to-equity near 1.1 while the firm shifts from growth to mature profitability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRefinancing pressure: CAD 1.2B debt\u003c\/li\u003e\n\u003cli\u003eFed rates ~5.25–5.50% (2024)\u003c\/li\u003e\n\u003cli\u003eDebt\/equity ~1.1\u003c\/li\u003e\n\u003cli\u003eCapex reprioritized; focus on cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora aims positive FCF by end‑2025 as cash burn trims to CAD40–60m run‑rate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora targets positive FCF by end‑2025 after cutting cash burn to a ~CAD 40–60m run‑rate; FY2024 COGS\/gram rose ~8% YoY due to energy\/labor, while Canadian recreational prices fell ~2% in 2024. FX volatility (EUR\/CAD ~0.8% daily, USD\/CAD ~0.9%) reduced FY2024 revenue by ~CAD 18–25m; hedges cover ~60–75% exposure. 2024 global cannabis M\u0026amp;A ~US$2.1bn; non‑cannabis revenue C$48m; debt ~CAD 1.2bn; D\/E ~1.1; Fed funds ~5.25–5.50%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash burn run‑rate\u003c\/td\u003e\n\u003ctd\u003eCAD 40–60m (2025 est)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\/gram\u003c\/td\u003e\n\u003ctd\u003e+8% YoY (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX impact on revenue\u003c\/td\u003e\n\u003ctd\u003e−CAD 18–25m (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHedging\u003c\/td\u003e\n\u003ctd\u003e60–75% coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon‑cannabis revenue\u003c\/td\u003e\n\u003ctd\u003eCAD 48m (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\u003c\/td\u003e\n\u003ctd\u003eCAD 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\/Equity\u003c\/td\u003e\n\u003ctd\u003e~1.1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal M\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e~US$2.1bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAurora PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Aurora PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use; no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751357985145,"sku":"auroramj-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/auroramj-pestle-analysis.png?v=1772230624","url":"https:\/\/growthsharematrix.com\/products\/auroramj-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}